Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic continues, with devasting consequences for human lives and the global economy1,2. The discovery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or prevent infection by this coronavirus. Here we report the isolation of sixty-one SARS-CoV-2-neutralizing monoclonal antibodies from five patients infected with SARS-CoV-2 and admitted to hospital with severe coronavirus disease 2019 (COVID-19). Among these are nineteen antibodies that potently neutralized authentic SARS-CoV-2 in vitro, nine of which exhibited very high potency, with 50% virus-inhibitory concentrations of 0.7 to 9 ng ml−1. Epitope…

• SF
  Simons Foundation

  Award: SF349247
• JF
  JPB Foundation
• T
  Tencent
• IA
  Innovation and Technology Commission
• NI
  National Institutes of Health

  Awards: U24 GM129539, GM103310
• NI
  National Institute of General Medical Sciences

  Awards: U24 GM129539, GM103310
• CF
  Common Fund

  Award: U24 GM129539